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Background. Patients with diabetes type 2 receiving dialysis
therapy have a poor survival prognosis, mainly due to cardio-
vascular events. Increased C-reactive protein (CRP) levels, im-
portant in atherosclerosis, are associated with an increased risk
for cardiovascular events. However, to date no study has shown
the predictive value of CRP in relation to peripheral arterial
disease stage.
Methods. We enrolled all 445 prevalent patients with diabetic
nephropathy receiving maintenance hemodialysis in 30 centers
in Southern Germany from August 1999 to January 2000 for
prospective study until December 2003. At inclusion, CRP and
a complete clinical phenotype, including peripheral arterial dis-
ease Fontaine Stage were determined. The primary end point
was all-cause mortality.
Results. A total of 305 (68.5%) patients died. An increased
log CRP at study inclusion was significantly associated with an
increase in hazard ratio (HR) by multivariate Cox regression
for all-cause (HR = 1.5, P = 0.002) and cardiac death (HR =
1.76, P = 0.02) in the entire collective. This result was applicable
only to patients with peripheral arterial disease Fontaine stage
IV (N = 190, multivariate HR = 1.75 for all-cause mortality,
P = 0.006). Possibly due to inadequate power, we observed only
an insignificant trend for CRP as predictor of all-cause death in
patients without peripheral arterial disease or with less severe
forms of peripheral arterial disease (HR = 1.36, P = 0.08).
Conclusion. In contrast to patients with peripheral arterial
disease stage IV, patients with less severe atherosclerosis and
elevated CRP are, if any, at less risk for cardiovascular mortality,
possibly due to the difference in extent of affected vasculature
and thus activated platelets and coagulation. Before judging the
predictive value of CRP for mortality, peripheral vessel status
should be determined.
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Patients receiving maintenance hemodialysis for end-
stage renal disease (ESRD) have a dismal survival and
morbidity prognosis [1, 2]. Cardiovascular events account
for almost 50% of deaths [3]. Peripheral arterial disease
has a prevalence of approximately 20% in incident dial-
ysis patients [4, 5], with 17% of patients having a history
of critical limb ischemia or knee amputation [5].
Local vascular inflammation, probably increased in di-
abetes mellitus due to the hyperglycemic state and oxida-
tive stress [6], is an important factor in the pathogenesis
of atherosclerosis [7]. C-reactive protein (CRP) may be a
valuable marker of this process [8, 9], while there is also
evidence for a causal role of CRP in atherosclerosis [10,
11]. There are ample data showing that increased CRP is
predictive for cardiovascular end points in healthy indi-
viduals [8, 9] and dialysis patients [12–20], but CRP has
been shown not to correlate well with the extent of vessel
surface affected by atherosclerosis [21]. It has not been
shown whether mortality risk predicted by CRP [8, 9,
12–20] is due to the extent of underlying atherosclerotic
morbidity, inflammation per se or a combination of both.
Recently, the importance of CRP relative to traditional
risk factors in predicting cardiovascular end points has
been questioned [9, 22, 23]. Remarkably, to date, there
is no data showing the predictive value of CRP levels in
patients in relation to peripheral artery disease stage, an
important risk factor possibly causing population strati-
fication [24]. Thus, we examined the role of CRP in pre-
dicting all-cause and cardiovascular mortality in a large
cohort of well-classified dialysis patients with type 2 dia-
betes mellitus in a prospective multicenter study.
METHODS
Subjects
A total of 445 Caucasian patients with type 2 diabetes
mellitus and ESRD were recruited from 30 dialysis cen-
ters in Southern Germany from August 1999 to January
2000. All prevalent patients of each dialysis center with
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Table 1. Clinical characteristics of patients with and without
peripheral arterial disease (PAD) stage IV
No PAD,
PAD stages I-III PAD stage IV
PAD stage IV (N = 255) (N = 190) P value
Male gender % 51.0 60.0 0.045
Age at inclusion years 67.6 ± 8.6 67.3 ± 7.7 0.65
Duration hemodialysis 2.3 ± 1.9 2.8 ± 2.4 0.016
at inclusion years
Diabetes duration at 14.3 ± 9.6 16.7 ± 9.4 0.01
start of dialysis years
Body mass index 27.0 ± 4.8 26.1 ± 4.0 0.04
Hemoglobin A1c % 6.94 ± 1.0 6.8 ± 1.3 0.3
C-reactive protein mg/L 11.5 ± 13.7 15.6 ± 17.8 0.005
Serum albumin g/L 42.5 ± 5.5 42.6 ± 4.8 0.5
present- or ex-smoker % 39.3 50.8 0.045
Coronary artery disease % 51.4 65.3 0.004
Myocardial infarction % 27.3 29.5 0.625
Coronary intervention % 16.7 20.0 0.38
Cerebral ischemia % 31.0 31.1 0.99
Angiotensin-converting 53.7 52.4 0.78
enzyme inhibitor %
Angtiotensin II type 1 15.3 13.8 0.65
receptor inhibitor %
Platelet inhibitor % 50.2 62.4 0.01
HMG-CoA inhibitor % 27.8 26.8 0.82
Calcium channel blocker % 47.8 45.5 0.625
Beta blocker% 29.4 20.6 0.036
Dialysis time per week hours 12.5 ± 1.2 12.8 ± 1.3 0.1
High-flux dialysis filter % 47.6 39.5 0.2
Biocompatible membrane % 77.9 69.9 0.13
Survival from inclusion years 2.67 ± 1.38 2.24 ± 1.39 0.001
HMG-CoA is 3-hydroxy-3-methylglutaryl coenzymeA. Statistical testing was
performed with v 2 or two-sided t test, where applicable.
diabetic nephropathy due to diabetes mellitus type 2 were
included. Diagnosis of diabetic nephropathy was either
confirmed by biopsy, or assumed if there was a typical clin-
ical course of longstanding diabetes mellitus successively
followed by microalbuminuria, proteinuria, and renal in-
sufficiency, in the absence of other causes of proteinuria.
Patients were recruited only if age was >35 years at diag-
nosis of diabetes mellitus. Patients with clinical signs of
systemic or overt local infection were excluded (N = 13).
Clinical characteristics of the patients are displayed in
Tables 1 and 2. The study was approved by the Ethics
Committee of the Medical Faculty of the University of
Regensburg [study number 97/38, “Genetic and Clin-
ical Predictors of Morbidity, Mortality and Diabetic
Nephropathy With End-Stage Renal Disease in Dia-
betes Mellitus Type 2—A Prospective Cohort Study”
(GENDIAN)]. All patients gave informed consent to par-
ticipation in the study.
Clinical parameters
At study inclusion, we determined cardiovascular risk
profile and morbidity, medication history, laboratory pa-
rameters relevant to cardiovascular diseases, dialysis fil-
ter type, and weekly duration of dialysis by questionnaire
and reviewing the patients’ charts. We determined date of
birth and of diagnosis of diabetes mellitus, nephropathy,
and beginning of dialysis therapy, respectively. Specifi-
cally, date of onset of diabetes mellitus was determined as
the date when a test for blood glucose was first abnormally
high (either fasting blood glucose or glucose tolerance
testing) and when the patient first took antidiabetic drugs.
In addition, the patient chart was reviewed to obtain the
date of diabetes onset. Peripheral arterial disease status
was classified clinically according to the Fontaine classi-
fication. Hereby, patients with angiographically proven,
asymptomatic atherosclerotic lesions of lower extremity
vessels were classified as Fontaine stage I, those with
intermittent claudication as stage II, and patients with
resting claudication as stage III. Patients with extremity
necrosis or amputation due to atherosclerotic vascular
disease were classified as Fontaine stage IV. Care was
taken not to misclassify patients with neuropathic foot
lesions as Fontaine stage IV. Patients were followed until
December 4, 2003. Primary end point was all-cause mor-
tality. Cause of death was assessed where possible. Death
due to myocardial infarction, cerebral ischemia, malig-
nant arrhythmia, intracerebral hemorrhage, or acute car-
diac failure was defined as the combined secondary end
point, “cardio- and cerebrovascular death” death due to
myocardial infarction, malignant arrhythmia, or acute
cardiac failure was defined as the combined secondary
end point, “cardiac death,” death, due to pneumonia or
septicemia of any cause as “infectious death” and death
due to trauma, gastrointestinal bleeding, cancer, or liver
cirrhosis was categorized as “other.”
Specimen collection
Ten milliliters whole blood samples were drawn prior
to hemodialysis sessions, and centrifuged within 6 hours.
Serum was frozen at −80◦C until analyses were per-
formed.
Serum parameters
CRP was determined with the C-Reactive Protein
Assay (Biomed, Oberschleissheim, Germany) (product
number 123440). The assay was calibrated for a detec-
tion range of 0.1 to 320 mg/L according to the instructions
of the producer. The intra-assay coefficients of variation
were 1.2%, 0.79%, and 0.91% for the CRP concentrations
2, 8, and 24 mg/L, respectively. The interassay coefficient
of variation was <2% for all concentrations.
Statistical analysis
Results are expressed as mean (±1 SD), unless
stated otherwise. CRP values were grouped in quartiles.
Comparisons of continuous variables between groups
were performed by Student t test, analysis of variance
(ANOVA), or by Kruskal-Wallis tests and of categoric
variables by v 2 or Fisher’s exact test where applicable.
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Table 2. Morbidity and causes of death of study collective
C-reactive protein quartiles mg/L
1 2 3 4
All patients (<3.7) (3.7 to 7.5) (7.51 to 17.35) (17.36 to 96.7)
(N = 445) (N = 111) (N = 111) (N = 112) (N = 111)
Coronary artery disease% 57.5 51.9 56.9 56.3 65.1
Myocardial infarction% 28.3 30.6 25.7 25.9 31.1
Coronary intervention% 18.2 16.7 19.3 20.5 16.0
Cerebral ischemia% 31.0 29.6 28.4 31.3 34.9
Peripheral arterial disease% 67.4 64.0 65.8 68.8 66.7
Fontaine stage I% 1.1 0 1.8 1.8 0.9
Fontaine stage II% 20.5 25.1 23.4 24.1 9.0
Fontaine stage III% 3.1 1.8 4.5 1.8 4.5
Fontaine stage IV% 42.7 36.9 37.8 42.9 53.2
Cardiovascular and cerebrovascular death% 118 (26.4) 19.8 27.5 24.1 34.2
Death due to infection% 55 (12.4) 8.1 13.8 15.2 12.6
Other cause of death% 19 (4.3) 5.4 3.7 5.4 2.7
Death cause unknown% 113 (23.7) 25.2 19.3 25.9 24.3
There are no differences in variables between C-reactive protein quartiles (v 2 analysis, P > 0.05).
Statistical significance in all tests was accepted at P <
0.05.
Survival analysis was performed by the Kaplan-Meier
method, comparing groups using the log-rank test. Cen-
soring is performed for renal transplantation (N = 9 in
non-peripheral arterial disease stage IV group and N =
2 in peripheral arterial disease stage IV group), loss to
follow-up (N = 2 in peripheral arterial disease stage
IV group) and if the patient is alive at the last exami-
nation (N = 41 in peripheral arterial disease stage IV
group, N = 86 in non-peripheral arterial disease stage
IV group). Duration of dialysis therapy from study in-
clusion onwards was the time variable if not indicated
otherwise. Covariates used for survival analysis and ex-
plorative statistics for comparison of patient groups were
log CRP (log of CRP value measured in mg/L), age
at start of dialysis therapy (years), duration of pre-
vious dialysis therapy and of diabetes at study inclu-
sion (years), gender (reference: female), smoking history
(reference: never-smoker), body mass index, systolic-
diastolic blood pressure difference prior to the dialy-
sis session at inclusion (mm Hg), serum albumin (g/L),
medication with angiotensin-converting enzyme (ACE)
or angtiotensin II (Ang II) receptor 1 antagonists, 3-
hydroxy-3-methylglutaryl coenzymeA (HMG-CoA) re-
ductase inhibitors, platelet inhibitors (acetylsalicylic acid,
ticlopidin, or clopidogrel) calcium channel antagonists
and beta blockers (reference: no therapy), presence of
coronary artery disease (reference: no coronary artery
disease), history of myocardial infarction and cerebral is-
chemia (reference: no such history) and history of coro-
nary intervention including bypass surgery (reference: no
intervention).
To correct for covariates, a Cox proportional hazard
ratio (HR) model was applied. First, the univariate HR
was determined for each variable in each subgroup (pa-
tients with peripheral arterial disease stage IV vs. patients
without peripheral arterial disease or with peripheral ar-
terial disease stages I to III). Different Cox regression
models were then performed with varying degrees of co-
variate adjustment. In model 1, effect of log CRP was
adjusted for age at start of dialysis and previous duration
of dialysis, in model 2 for age at start of dialysis therapy,
previous duration of dialysis therapy, gender, smoking
history and body mass index. In model 3, medication his-
tory was added in addition to the variables of model 2. In
the extended model 4, all covariates were included. The
fully adjusted model 4 was used to examine the effect of
log CRP on secondary end points.
We found significant statistical interaction of periph-
eral arterial disease status and log CRP in the multivari-
ate Cox model 4 [HR for (log CRP) ∗ (peripheral arte-
rial disease status) = 1.75 (P = 0.03); HR for log CRP
= 1.07 (P = 0.72); HR for peripheral arterial disease sta-
tus = 0.91 (P = 0.47)]. The likelihood ratio (LR) test for
comparison of the log-likelihood statistics for the inter-
action model [(peripheral arterial disease status) ∗ (log
CRP), peripheral arterial disease status, log CRP, and all
other variables of model 4 set as covariates] and the no-
interaction model (log CRP and peripheral arterial dis-
ease status and all variables of model 4 set as covariate)
was performed and found to be significant (P < 0.05).
Power calculations for survival analysis were per-
formed separately for each patient subgroup with the
PS Power and Sample Size Calculations software pack-
age, version 2.1.30 [25]. Since available software does not
support power calculation for studies in which the expo-
sition variable is continuous, patients with a CRP value
less than median CRP were classified as control group,
whereas patients with a CRP value greater than or equal
to median CRP were classified as the exposition group.
For patients without peripheral arterial disease or with
peripheral arterial disease stages I to III, the study was
powered with 0.8 to detect a HR of 1.42 and of 0.9 to
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detect a HR of 1.51, both with a 0.05 type I error proba-
bility. For patients with peripheral arterial disease stage
IV, the study was powered with 0.8 to detect a HR of 1.5
and with 0.9 to detect a HR of 1.6, both with a 0.05 type
I error probability.
For analysis of the effect of dialysis membrane type
on inflammation, high-flux dialysis was defined as an ul-
trafiltration coefficient >20 mL/hour/mm Hg and low-
flux dialysis was defined as an ultrafiltration coefficient
<20 mL/hour/mm Hg. Good biocompatibility was as-
sumed for polysulfone, polyamide, and BiomembraneTM
filters, whereas low biocompatibility was assumed for
HemophanR and cellulose acetate filters [26, 27]. A total
of 52.2% of the patients were dialysed with polysulfone,
21.4% with HemophanR, 11.6% with polyamide, 10.9%
with BiomembraneTM, and 4.0% with cellulose acetate.
The distribution of membrane materials among patients
with and without peripheral arterial disease stage IV did
not differ significantly (Table 1) (v 2 test, P > 0.05).
Statistical analysis was performed with the SPSS ver-
sion 11.5 software package (Chicago, IL, USA).
RESULTS
CRP quartiles and dialysis membrane type
CRP values were not normally distributed. Log10 trans-
formation was performed to achieve normal distribution.
In our study population (N = 445), mean CRP was
13.25 ± 15.7 mg/L (median = 7.5, range = 0.16–96.7).
CRP in quartile 1 was 0.16 to 3.69 mg/L, 3.7 to 7.5 mg/L
in quartile 2, 7.51 to 17.35 mg/L in quartile 3, and 17.36 to
96.7 mg/L in quartile 4. In patients with peripheral arterial
disease stage IV (N = 190), CRP in quartile 1 was 0.16
to 4.27 mg/L, 4.67 to 8.6 mg/L in quartile 2, 8.65 to 19.76
mg/L in quartile 3, and 20.03 to 93.08 mg/L in quartile
4. In patients without peripheral arterial disease or with
peripheral arterial disease stages I to III (N = 255), CRP
in quartile 1 was 0.17 to 3.09 mg/L, 3.24 to 6.53 mg/L in
quartile 2, 6.58 to 14.6 mg/L in quartile 3, and 14.66 to
96.7 mg/L in quartile 4.
The use of low- and high-flux dialysers and of bio-
compatible membranes was evenly distributed across the
CRP quartiles in the complete collective and in both
subgroups. In addition, mean CRP values did not dif-
fer significantly between filter categories, though there
was a trend for lower CRP values in patients dialysed
with a high-flux (patients without peripheral arterial dis-
ease stage IV, CRP 9.6 ± 10.3 mg/L; patients with pe-
ripheral arterial disease stage IV, CRP 11.4 ± 11.2mg/L)
or a biocompatible membrane (patients without periph-
eral arterial disease stage IV, CRP 10.9 ± 13.1 mg/L;
patients with peripheral arterial disease stage IV, CRP
12.3 ± 12.5 mg/L) in comparison with patients dialysed
with a low-flux (patients without peripheral arterial dis-
ease stage IV, CRP 12.9 ± 15.9 mg/L; patients with periph-
eral arterial disease stage IV, CRP 14.9 ± 15.9 mg/L) or
a poorly biocompatible membrane (patients without pe-
ripheral arterial disease stage IV, CRP 13.2 ± 15.5 mg/L;
patients with peripheral arterial disease stage IV, CRP
16.4 ± 17.7 mg/L).
Anthropometric variables by CRP quartiles
Significant differences between the CRP quartiles were
observed in the male/female ratio and in smoking his-
tory only. In the upper quartiles, there were more males
(65.8% vs. 37.8% males in quartile 4 and 1, respectively)
(P < 0.001) and patients with a smoking history (P = 0.04,
degrees of freedom = 6) than predicted by v 2 analysis.
Anthropometric variables by gender
In a separate analysis of males and females, there was a
trend for more males in the upper CRP quartiles having
a smoking history, which was statistically not significant
[for females (v 2 = 3.7, df = 3, P = 0.30) and for males
(v 2 = 0.42, df = 3, P = 0.94)]. However, more females
in the higher CRP quartiles had a history of cerebral is-
chemia (v 2 = 8.35, df = 3, P = 0.039). In addition, females
in the higher CRP quartiles had a statistically significant
shorter history of diabetes (ANOVA F = 3.02, df = 3, P =
0.031) and were older at diagnosis of diabetes (ANOVA
F = 3.5, df = 3, P = 0.017). All other variables showed
no difference between the CRP quartiles when analyzed
by gender.
Anthropometric variables and survival by peripheral
arterial disease status
As expected, patients with peripheral arterial disease
stage IV had more risk factors for atherosclerosis and
more frequently had coronary artery disease than pa-
tients without peripheral arterial disease or with less se-
vere peripheral arterial disease. In the comparison of
patients with peripheral arterial disease stage IV with
patients without peripheral arterial disease or with pe-
ripheral arterial disease stages I to III, significant dif-
ferences were observed in several variables (Table 1).
Importantly, male gender, coronary artery disease, smok-
ing history, and use of platelet aggregation inhibitors were
more frequent in the group of patients with peripheral
arterial disease stage IV. Beta blockers were used more
frequently in patients without peripheral arterial disease
or with peripheral arterial disease stages I to III. Also, du-
ration of prior dialysis therapy and of diabetes at study in-
clusion was higher in the peripheral arterial disease stage
IV group.
In a separate analysis of patients with peripheral ar-
terial disease stage IV (N = 190) and of patients with
no peripheral arterial disease or with peripheral arterial
disease stages I to III (N = 255), significant differences
between CRP quartiles were observed in gender and
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Fig. 1. Kaplan-Meier analysis of survival on hemodialysis therapy by
peripheral arterial disease (PAD) status (N = 445). Log rank = 13.4,
P = 0.0003.
smoking history only. In both subgroups, males were
more frequent (P < 0.01) and patients more frequently
had a smoking history (P < 0.05) in the upper CRP quar-
tiles. There were no other differences between CRP quar-
tiles when analyzed by peripheral arterial disease stage.
Importantly, there was a significant difference in sur-
vival when comparing the peripheral arterial disease
groups. From study inclusion onwards, patients with pe-
ripheral arterial disease stage IV had a mean survival of
2.24 ± 1.39 (N = 147/190 deaths), and patients without
peripheral arterial disease stage IV had a mean survival
of 2.67 ± 1.38 years (N = 158/255 deaths) (P = 0.001)
(Table 1). The increase in risk for mortality in periph-
eral arterial disease stage IV patients was confirmed in
Kaplan-Meier (Fig. 1) and Cox regression analysis [mul-
tivariate HR (Cox model 4, excluding log CRP) for pe-
ripheral arterial disease status (peripheral arterial disease
stages I to III and no peripheral arterial disease set as ref-
erence variable) = 1.55, 95% CI 1.21 to 1.98, P < 0.001].
Morbidity and mortality by CRP quartiles
Presence or history of coronary artery disease, myocar-
dial infarction, coronary intervention, peripheral arte-
rial disease, and cerebral ischemia was evenly distributed
amongst the CRP quartiles (P > 0.05) (Table 2).
Of the 445 patients, 305 (68.5%) had died at the fi-
nal examination. Mean follow-up time for patients with
an event, defined as all-cause mortality, was 1.84 years
(±1.13 years), and 3.90 years (±0.77 years) for patients
without an event. An event occurred significantly more
frequently in patients in the upper CRP quartiles [quar-
tile 1, 68 (61.3%) events; quartile 2, 71 (64.0%) events;
quartile 3, 80 (72.1%) events; quartile 4, = 86 (77.5%)
events] (v 2 = 8.35, df = 3, P = 0.039).
The causes of death, as determined by review of the
patient chart and interview of the dialysis physician, are
shown in Table 2. One hundred thirteen (37.1%) of all
mortalities were of unknown cause or the cause could
not definitely be determined. There were no significant
differences between CRP quartiles in categories of death
causes.
Clinical characteristics of patients with and
without mortality
At study inclusion, patients had received a mean of 2.55
years (±2.1 years) of dialysis therapy. There was no signif-
icant difference by two-sided t test in prior dialysis dura-
tion between patients with (2.6 ± 2.2 years) or without an
event (2.4 ± 1.9 years) (P = 0.2), defined as all-cause mor-
tality. In contrast, patients with an event were older at ini-
tiation of dialysis than patients without an event (66.2 ±
8.2 years vs. 62.1 ± 9.0 years) (P < 0.001), more frequently
had peripheral arterial disease stage IV (48.2% vs. 30.7%)
(v 2 = 11.99, P = 0.001), a history of coronary artery dis-
ease (60.6% vs. 50.4%) (v 2 = 3.95, P = 0.047), myocardial
infarction (33.4% vs. 16.5%) (v 2 = 13.0, P < 0.001), and
cerebral ischemia (34.4% vs. 23.3%) (v 2 = 5.3, P = 0.021)
than patients without an event. Therapy with HMG-CoA
reductase inhibitors was associated with less frequent oc-
currence of events (v 2 = 7.1, df = 1, P = 0.008). All other
variables showed no differences in patients with or with-
out an event. Specifically, the number of events did not
differ by gender (v 2 = 0.4, df = 1, P = 0.53).
Survival as determined by baseline CRP
Kaplan-Meier analysis showed a significant increase in
risk for all-cause mortality with increasing CRP quartiles
(Fig. 2A) (log rank statistic = 18.43, df = 3, P = 0.0004).
In univariate and multivariate Cox regression survival
analysis of the complete collective (N = 445), there was
an increased risk for all-cause mortality with increasing
CRP quartile with the lowest quartile set as the reference
category (multivariate analysis by model 4, HR for CRP
quartile 2 = 1.19, P = 0.33; HR for CRP quartile 3 = 1.67,
P = 0.004; HR for CRP quartile 4 = 1.77, P = 0.002). An
increase in log CRP was associated with an increase in all-
cause mortality in the complete collective (multivariate
HR by model 4 for log CRP = 1.5, P = 0.002).
CRP as a predictor of all-cause mortality in relation to
peripheral arterial disease stage
In univariate analysis, the covariates defined in the
Methods section had different effects on mortality in
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Fig. 2. Kaplan-Meier analysis of survival on hemodialysis therapy by C-reactive protein (CRP). Evaluation by quartile (A) (N = 445). End point
is all-cause mortality. Patients are censored for renal transplantation (N = 11), lost to follow-up (N = 2), or if alive on December 4, 2003 (N =
127). Triangles represent censored patients. Log rank = 18.43, df = 3, P = 0.0004. (B) Peripheral arterial disease stage IV (N = 190). End point is
all-cause mortality (N = 147). Patients are censored for renal transplantation (N = 2), or if alive on December 4, 2003 (N = 41). Triangles represent
censored patients. Log rank statistic = 10.7, df = 3, P = 0.01. (C) Patients with peripheral arterial disease other than Fontaine stage IV or without
peripheral arterial disease (N = 255). End point is all-cause mortality (N = 158). Patients are censored for renal transplantation (N = 9), lost to
follow-up (N = 2), or if alive on December 4, 2003 (N = 86). Triangles represent censored patients. Log rank = 3.72, df = 3, P = 0.29.
patients with and without peripheral arterial disease stage
IV, including log CRP (Table 3). The increase in mor-
tality risk with increased CRP was observed only in
patients with Fontaine stage IV peripheral arterial dis-
ease. CRP did not predict mortality for patients with
no known peripheral arterial disease or with Fontaine
stage I, II and III peripheral arterial disease (Fig. 2B
and C).
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Table 3. Univariate Cox proportional hazard regression analysis of survival on hemodialysis therapy, giving the hazard ratio (HR) for each of the
covariates used in multivariate analysis
No PAD, PAD stages I to III PAD stage IV
(N = 255) (N = 190)
Covariate HR (95% CI) P value HR (95% CI) P value
Log C-reactive protein 1.3 (0.95–1.77) 0.1 1.89 (1.34–2.66) <0.001
Age at dialysis initiation (per year increase) 1.04 (1.02–1.06) <0.001 1.02 (1.01–1.04) 0.04
Dialysis duration prior to study (per year increase) 0.97 (0.89–1.06) 0.52 1.08 (1.02–1.15) 0.01
Diabetes duration at study inclusion (per year increase) 1.0 (0.98–1.01) 0.57 1.0 (0.98–1.02) 0.73
Myocardial infarction (no infarction) 1.62 (1.16–2.27) 0.005 1.48 (1.05–2.08) 0.03
Coronary intervention or surgery (no intervention) 0.63 (0.4–1.01) 0.06 0.75 (0.5–1.14) 0.18
Cerebral ischemia (no ischemia) 1.35 (0.97–1.88) 0.07 1.03 (0.73–1.45) 0.86
Gender (female) 1.23 (0.9–1.67) 0.2 0.94 (0.67–1.3) 0.69
Smoking history (never-smoker) 1.04 (0.75–1.44) 0.8 1.06 (0.77–1.47) 0.73
Therapy with platelet inhibitor (no therapy) 1.04 (0.76–1.42) 0.8 0.68 (0.49–0.95) 0.02
Therapy with HMG-CoA reductase inhibitors (no therapy) 0.69 (0.48–0.99) 0.05 0.65 (0.44–0.95) 0.03
Serum albumin (per g/L increase) 0.97 (0.44–1.0) 0.09 0.97 (0.94–0.99) 0.03
Therapy with beta blocker (no therapy) 0.89 (0.63–1.27) 0.52 0.75 (0.49–1.14) 0.17
Therapy with calcium channel antagonist (no therapy) 0.91 (0.66–1.24) 0.54 0.83 (0.6–1.15) 0.17
Therapy with angiotensin-converting enzyme or
angiotensin II receptor inhibitor (no therapy)
1.05 (0.75–1.46) 0.78 0.99 (0.71–1.38) 0.96
Pulse pressure (per mm Hg increase) 1.0 (0.99–1.01) 0.87 1.0 (0.99–1.01) 0.46
History of coronary artery disease (no history) 1.29 (0.94–1.77) 0.12 1.08 (0.76–1.52) 0.67
Body mass index (per unit increase) 0.96 (0.93–0.99) 0.03 0.97 (0.93–1.01) 0.55
PAD is peripheral arterial disease and HMG-CoA is 3-hydroxy-3-methylglutaryl coenzymeA.
Table 4. Multivariate Cox proportional hazard regression model of survival on hemodialysis therapy
No PAD, PAD stages I to III PAD stage IV
(N = 255) (N = 190)
Cox regression model HR 95% CI P value HR 95% CI P value
Log C-reactive protein model 1 1.3 0.96–1.75 0.09 2.02 1.42–2.87 <0.001
Log C-reactive protein model 2 1.25 0.91–1.72 0.18 2.01 1.4–2.88 <0.001
Log C-reactive protein model 3 1.25 0.9–1.73 0.19 1.99 1.37–2.88 <0.001
Log C-reactive protein model 4 1.36 0.97–1.93 0.08 1.75 1.18–2.6 0.006
PAD is peripheral arterial disease. The time variable is survival from study inclusion onward. All-cause mortality is defined as event. Model 1, age-adjusted; model 2,
adjusted for age and hemodialysis duration at inclusion, gender, smoking history, and body mass index; model 3, adjusted for medication and covariates of model 2; and
model 4, adjusted for all covariates.
Multivariate hazard ratios of log CRP for all-cause
mortality for the group with peripheral arterial disease
stage IV and for the group without peripheral arterial
disease or with peripheral arterial disease stages I to III
were 1.75 (P = 0.006) and 1.36 (P = 0.08), respectively
(Table 4).
CRP as a predictor of secondary end points
Higher log CRP significantly increased risk of cardio-
and cerebrovascular death in the combined collective
(N = 445) by univariate Kaplan-Meier (for cardiac death,
log rank = 17.4, df = 3, P = 0.0006) and multivariate anal-
ysis (for cardiac death, HR = 1.76, P = 0.02). The causes
of 37.1% (N = 113) of all deaths could not definitely be
determined. Classifying the undetermined events as car-
diac death yields a HR for log CRP for cardiac death of
1.67 (95% CI 1.23 to 2.27, P = 0.001). Again, log CRP was
a better predictor of cardiovascular end points in patients
with peripheral arterial disease stage IV (Table 5).
Subgroup analysis of patients matched for dialysis
duration and coronary artery disease
The two patient groups (peripheral arterial disease
stage IV and peripheral arterial disease stages I to III
or no peripheral arterial disease differed significantly in
several variables (Table 1). In a substudy, we matched
the two groups for prior duration of dialysis therapy and
presence of coronary artery disease. In this subgroup
(N = 350) (patient characteristics not shown), log CRP
significantly predicted all-cause death in peripheral arte-
rial disease stage IV patients (multivariate HR = 1.73,
P = 0.008), but not in patients without peripheral arterial
disease or with peripheral arterial disease stages I to III
(multivariate HR = 1.27, P = 0.24).
Subgroup analysis of patients matched for CRP
In a further substudy, we matched the two groups for
CRP values. In this subgroup (N = 350) (patient charac-
teristics not shown), CRP did not differ between patients
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Table 5. Hazard ratio (HR) of log C-reactive protein (CRP) for secondary end points, determined by multivariate Cox regression analysis (model
4) in the subgroups with and without peripheral arterial disease (PAD) stage IV
No PAD, PAD stages I to III PAD stage IV
HR of log CRP HR of Log CRP
Combined secondary end point (N = 255) P value (N = 190) P value
Cardiac death 1.57 (N = 47) 0.14 2.73 (1.23-6.1) (N = 47) 0.01
Cardiovascular death 1.47 (N = 61) 0.15 2.12 (1.1-4.25) (N = 57) 0.03
Infectious death 1.59 (N = 24) 0.38 1.24 (N = 31) 0.62
Cardiac death and death of unknown cause 1.41 (N = 109) 0.11 2.24 (1.36-3.7) (N = 98) 0.002
End points are defined as death due to cardiac causes, cardiovascular causes, or infectious complications as defined in the Methods section. Numbers given represent
number of deaths due to the specified end point. The time variable is survival from study inclusion onwards.
with or without peripheral arterial disease stage IV (pa-
tients without peripheral arterial disease stage IV, mean
CRP 12.6 ± 14.6; patients with peripheral arterial dis-
ease stage IV, mean CRP 13.9 ± 16.9, P > 0.05). Again,
log CRP was a significant predictor of all-cause mortality
only in patients with peripheral arterial disease stage IV
(peripheral arterial disease stage IV, multivariate HR =
2.03, P = 0.001; no peripheral arterial disease, peripheral
arterial disease stages I to III, multivariate HR = 1.37,
P = 0.17).
DISCUSSION
To our knowledge, this is the first study on type 2 dia-
betic hemodialysis patients demonstrating that CRP has
a significant predictive value for all-cause death only in
patients with peripheral arterial disease in Fontaine stage
IV. In patients with less severe peripheral arterial disease
and in patients without peripheral arterial disease, an el-
evated CRP shows a trend for predicting all-cause death
that is not significant or too small to be detected by our
study’s power. The same was shown for the secondary
end points of cardiac and cardiovascular death.
Previous studies on healthy probands and hemodialy-
sis patients have uniformly shown a significant associa-
tion of death with an increased CRP at baseline, mainly
due to cardiovascular causes [8, 9, 12–20]. In the stud-
ies on hemodialysis patients [12–20], CRP values and the
quartile ranges were comparable to those observed in our
study, suggesting a similar inflammatory state.
In contrast to our study, previous publications have not
characterised the degree of peripheral arterial disease in
the patient collectives studied. Currently, it is hypothe-
sised that the increased CRP observed in dialysis patients
reflects the severity of an “inflammatory state,” caused in
parts by dialysis itself [28], vessel inflammation due to
atherosclerosis [12, 14], and oxidative stress [29]. By this
theory, a high level of inflammatory activity, as reflected
by elevated CRP, is associated with an increased mortality
risk. However, our data may further specify this hypothe-
sis. Elevated CRP appears to be of relevance to outcome
especially in patients with a “critical mass” of severe arte-
rial atherosclerosis. It is well known that patients with sig-
nificant peripheral arterial disease have an increased risk
for several adverse outcome parameters such as death
with acute myocardial infarction and hospital admission
[4]. Given a large surface of thus affected vasculature
as encountered in peripheral arterial disease stage IV, a
procoagulant state will ensue [30–34]. Activated platelets
appear to play an important role in promoting leuko-
cyte binding to affected endothelium and in progression
of atherosclerosis via delivery of the chemokine regu-
lated on activation, normal T-cell expressed and secreted
(RANTES) and of platelet factor 4 [35, 36]. The addi-
tional presence of systemic inflammation, irrespective of
its origin, may then be the factor “tipping the scale”
toward catastrophic cardiovascular events, possibly by
directly activating endothelial cells [37] or by other mech-
anisms. Patients with less severe atherosclerosis are less
likely to have a significant surface of atherosclerotic ves-
sels causing a relevant procoagulant state.
A recent study showed only a modest role of CRP in
predicting cardiac events [9], in contrast to the results
of other large studies on healthy probands [8]. In both
studies, peripheral arterial disease status was not shown.
The importance of peripheral arterial disease severity for
mortality risk due to CRP elevation shown in our study,
though in a markedly different collective, may in part ex-
plain the discrepancy of the predictive value of CRP. If
the number of patients with significant peripheral arterial
disease differs significantly between studies the study co-
horts would be differently stratified and would thus yield
varying hazard ratios for CRP.
In support of our data, deFilippi et al [13] showed
that dialysis patients with elevated CRP values are more
prone to suffer fatal cardiac events only if they have sig-
nificant coronary artery disease, defined by elevated car-
diac troponin T. An “inflammatory milieu” was thought
to trigger the event in these patients, while the role of
peripheral arterial disease status was not examined.
The relative role of CRP caused by the dialysis pro-
cess itself or by the membranes used, by subclinical
infection or by chronic vascular inflammation in predict-
ing mortality was not the subject of examination in our
study and, to our knowledge, in other studies. A study
on peritoneal dialysis patients [15] had a lower median
Bo¨ger et al: CRP and peripheral arterial disease in dialysis 225
CRP value than in our study and other studies on CRP
in hemodialysis patients (2.84 mg/L vs. 7.5 mg/L). As in
our study, baseline CRP at study inclusion was a signif-
icant predictor of mortality. One may hypothesize that
the difference in CRP can be ascribed to a proinflam-
matory effect of hemodialysis membranes, since all other
anthropometric data are grossly comparable in all studies.
In support of this theory, we found a nonsignificant trend
for higher CRP values in patients dialysed with a low flux
or with a poorly biocompatible membrane. Interestingly,
a higher dialysis dose and the use of high-flux filters did
not influence survival in a large prospective randomized
controlled study [38]. However, since the use of poorly
biocompatible membranes was excluded and CRP values
and peripheral arterial disease status were not reported,
the effect of the dialysis process on inflammation cannot
be deduced from that study. A further prospective study
with well-matched patients may clarify this issue. How-
ever, the presence of subclinical infection would also be
an important variable in such studies examining the role
of inflammation in atherosclerosis.
In our study population, the prevalence of peripheral
arterial disease was higher than in other studies examin-
ing the effect of CRP on mortality (67.4% vs. approxi-
mately 25%). We ascribe this to the fact that all the pa-
tients in our study have diabetes mellitus type 2, whereas
other studies included 16% to 50% patients with diabetes
[12–20]. In patients with diabetes mellitus, accelerated
atherosclerosis appears to be the consequence of forma-
tion of advanced glycation end products due to hyper-
glycemia and oxidative stress [6], a process that may be
fuelled by concomitant inflammation.
Peripheral arterial disease status was determined
clinically according to Fontaine’s classification. Ankle
brachial index could not be determined due to vessel cal-
cification in the majority of patients (data not shown). We
cannot exclude that Fontaine classification would not cor-
relate with angiography results in our population. How-
ever, we feel that Fontaine’s classification of peripheral
arterial disease stage is a practical, low-cost clinical tool
for judging the severity of peripheral atherosclerotic dis-
ease.
In contrast to the data of Stenvinkel et al [17], males
and females in our cohort had no statistically significant
different survival when stratified for normal (CRP <3.7
mg/L) and elevated CRP (data not shown). Ethnically,
the two cohorts may not be comparable and mean age
at study inclusion in our cohort was higher (67.5 ± 8.2
years vs. approximately 60 years). More important, the
two cohorts may have differed significantly in prevalence
of peripheral arterial disease stage IV. In our population,
46.9% (N = 115) of males and 37.5% (N = 75) of females
had peripheral arterial disease stage IV. Given our find-
ing that peripheral arterial disease stage is an important
factor in judging the relevance of an elevated CRP value,
a significantly different male/female ratio of patients with
peripheral arterial disease stage IV in the cited study may
then explain the discrepancy in results.
To minimize selection bias [24], we analyzed whether
more high-risk patients (e.g., higher age, history of coro-
nary artery disease, smoking) were included in the higher
CRP quartiles in the subgroup with peripheral arterial
disease stage IV than in the subgroup with no or with
less severe peripheral arterial disease. Indeed, in both
the subgroups and in the complete collective, there were
more males and patients with a smoking history in the up-
per than in the lower CRP quartiles, whereas in all other
parameters there were no differences between quartiles
in all groups. However, we do not see a relevant bias in
this fact since this phenomenon was observed to a simi-
lar degree in patients with or without peripheral arterial
disease stage IV.
Further, patients with or without peripheral arterial
disease stage IV differed in several variables (Table 1).
Possibly, the difference in effect of CRP on mortality may
be ascribed to this fact. However, after post hoc match-
ing for prior dialysis duration and presence of coronary
artery disease, CRP was again associated with a signif-
icant increase in mortality in peripheral arterial disease
stage IV patients only. This suggests that, while being
statistically significant, the differences in anthropometric
data between the subgroups may be negligible as to the
effect of CRP.
Since CRP differed between subgroups, we performed
post hoc matching for CRP value. Again, log CRP was a
significant predictor of primary and secondary end points
only in peripheral arterial disease stage IV, suggesting
that the significant difference in CRP values in the to-
tal collective between the subgroups has no effect on the
overall results. Nonetheless, we cannot exclude that strat-
ification of the population may have influenced the results
of our study.
A comparison of log CRP HRs between peripheral ar-
terial disease groups is statistically not tenable. Though
hazard due to an increase in log CRP is nominally higher
in peripheral arterial disease stage IV patients than in
patients without peripheral arterial disease stage IV, one
should not conclude that mortality risk is higher. How-
ever, there was a significant effect of log CRP on survival
in patients with peripheral arterial disease stage IV but
not in patients without peripheral arterial disease stage
IV, even though patient number was higher in the no pe-
ripheral arterial disease stage IV group than in patients
with peripheral arterial disease stage IV.
Formal testing showed significant interaction between
log CRP and peripheral arterial disease status, support-
ing our conclusion. However, in the interaction Cox re-
gression model, peripheral arterial disease status and log
CRP was found to have no significant effect on survival.
Since this is in sharp contrast to our data (Figs. 1 and 2)
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and that of others [12–20], it is reasonable to question
whether the statistical interaction model correlates with
biologic reality. The statistical analysis of biologic interac-
tion is methodologically complex and has been regarded
as error-prone [39]. In our opinion however, the highly
significant, 55% difference in mortality risk between pe-
ripheral arterial disease groups in our study (multivari-
ate analysis of effect of peripheral arterial disease status
on mortality) supports our approach that these groups
should not be compounded to one single group but rather
placed in separate analyses, irrespective of the exposition
variable of interest.
CONCLUSION
Our data suggest that the degree of atherosclerosis
plays at least a similar role as that of the severity of mea-
sured systemic inflammation in predicting mortality in
dialysis patients. In type 2 diabetic dialysis patients, it is
the presence of severe generalized atherosclerosis that
appears to prepare the ground for a high mortality risk
due to elevated inflammatory parameters. Thus, before
judging the predictive value of CRP for mortality or car-
diovascular end points, peripheral vessel status should be
determined. Given the dismal prognosis of diabetic pa-
tients with peripheral arterial disease on hemodialysis,
the challenge to medical research lies in the prevention
and treatment of generalized atherosclerosis complicated
by inflammation.
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